中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

11 records (took 0.018 seconds)

    PEPTIDE FOR TREATING INFLAMMATION AND WOUNDS
    1.
    发明申请
    PEPTIDE FOR TREATING INFLAMMATION AND WOUNDS 有权

    公开(公告)号：US20220242904A1

    公开(公告)日：2022-08-04

    申请号：US17718758

    申请日：2022-04-12

    Applicant: NIBEC CO., LTD. ,  SEOUL NATIONAL UNIVERSITY R&B FOUNDATION

    Inventor： Yoon Jeong Park ,  Chong-Pyoung Chung ,  Jue-Yeon Lee

    IPC: C07K2/00 ,  A61P29/00 ,  A61P37/06 ,  A61P19/02 ,  A61P1/04 ,  A61P17/06 ,  A61P17/02

    Abstract: The present invention relates to a peptide for treating inflammation and wounds and, more specifically, to use of a peptide for treating inflammation and wounds, wherein the peptide binds to collagen type VII exposed by damage to tissue and recognizes collagen type VII as an antigen, thereby inhibiting the induction of an immune response, and thus having a function of inhibiting inflammation caused by an autoimmune response, and has the function of promoting wound healing by promoting cell proliferation and migration to a wound site in the damaged tissue. The peptide according to the present invention has the binding ability to collagen type VII, and thus inhibits an immune response caused by collagen type VII, thereby inhibiting inflammation caused by an autoimmune response. In addition, the peptide can bind to the integrin beta 1 of intestinal epithelial cells and increase the cell adhesion and migration via phosphor-FAK signal and tight junction markers are increased via FAK-RhoA signal and thus promote intestine regeneration.

    NOVEL PEPTIDE CAPABLE OF BINDING TO BIOMARKER FOR INFLAMMATORY AND METABOLIC DISEASES, AND USE THEREOF
    7.
    发明申请
    NOVEL PEPTIDE CAPABLE OF BINDING TO BIOMARKER FOR INFLAMMATORY AND METABOLIC DISEASES, AND USE THEREOF 有权

    公开(公告)号：US20210355164A1

    公开(公告)日：2021-11-18

    申请号：US17271739

    申请日：2019-08-29

    Applicant: NIBEC CO., LTD.

    Inventor： Yoon Jeong Park ,  Chong-Pyoung Chung ,  Jue-Yeon Lee

    IPC: C07K7/08 ,  A61P1/16 ,  A61P1/00

    Abstract: The present invention pertains to: a peptide having ATF3-binding ability and represented by any one amino acid sequence selected from the group consisting of SEQ ID NOs: 1 to 4; a fused peptide in which a cell-permeable peptide is bound to the peptide having ATF3-binding ability; and a use of the peptides for the treatment of inflammatory diseases, metabolic diseases, autoimmune diseases and/or fibrotic diseases. According to the present invention, a novel peptide having the ability to bind to ATF3, which is a protein serving as a biomarker and an important factor in the occurrence of various inflammatory diseases, metabolic diseases, autoimmune diseases and/or fibrotic diseases, is provided to thereby regulate the intracellular concentration of ATF3, and can thus be used for the treatment of inflammatory diseases, metabolic diseases, autoimmune diseases and/or fibrotic diseases. Moreover, the disease treatment effect can be enhanced by further fusing a peptide having intracellular permeability and an inflammation inhibitory function to the peptide.

    NOVEL USE OF PEPTIDE FOR INHIBITING FUNCTIONS AND EXPRESSIONS OF MULTIPLE DISEASE BIOMARKERS
    8.
    发明公开
    NOVEL USE OF PEPTIDE FOR INHIBITING FUNCTIONS AND EXPRESSIONS OF MULTIPLE DISEASE BIOMARKERS 审中-公开

    公开(公告)号：US20240166688A1

    公开(公告)日：2024-05-23

    申请号：US18385640

    申请日：2023-10-31

    Applicant: NIBEC CO., LTD.

    Inventor： Yoon Jeong Park ,  Chong-Pyoung Chung ,  Jue-Yeon Lee

    IPC: C07K7/08 ,  A61K45/06

    CPC classification number: C07K7/08 ,  A61K45/06 ,  A61K38/00

    Abstract: The present invention relates to a novel use of a peptide for inhibiting the functions and expressions of multiple disease biomarkers, and more specifically, to a pharmaceutical composition for treating or preventing inflammation, metabolic diseases or fibrotic diseases, the composition comprising, as an active ingredient, any one or more peptide among peptides which are represented by the amino acid sequences of SEQ ID NOs: 1 to 8, and which, for histone deacetylase 5 (HDAC5), GDF15 and ATF3 which are biomarkers associated with inflammation, metabolic diseases or fibrotic diseases, have the functions of inhibiting HDAC5 phosphorylation, inhibiting the expression of the GDF15 protein and inhibiting the expression of the ATF3 protein. The peptide, according to the present invention, enables the triple-blocking of the biomarkers associated with inflammation, metabolic diseases or fibrotic diseases by inhibiting HDAC phosphorylation, inhibiting the expression of the GDF15 protein and inhibiting the expression of the ATF3 protein, and thus the production of inflammatory cytokine may be reduced, and thus the peptide is effective in preventing and treating inflammatory, metabolic or fibrotic diseases.

    Peptide capable of binding to biomarker for inflammatory and metabolic diseases, and use thereof
    9.
    发明授权
    Peptide capable of binding to biomarker for inflammatory and metabolic diseases, and use thereof 有权

    公开(公告)号：US11384120B2

    公开(公告)日：2022-07-12

    申请号：US17271739

    申请日：2019-08-29

    Applicant: NIBEC CO., LTD.

    Inventor： Yoon Jeong Park ,  Chong-Pyoung Chung ,  Jue-Yeon Lee

    IPC: C07K7/08 ,  A61K38/00 ,  A61P1/16 ,  A61P1/00

    Abstract: The present invention pertains to: a peptide having ATF3-binding ability and represented by any one amino acid sequence selected from the group consisting of SEQ ID NOs: 1 to 4; a fused peptide in which a cell-permeable peptide is bound to the peptide having ATF3-binding ability; and a use of the peptides for the treatment of inflammatory diseases, metabolic diseases, autoimmune diseases and/or fibrotic diseases. According to the present invention, a novel peptide having the ability to bind to ATF3, which is a protein serving as a biomarker and an important factor in the occurrence of various inflammatory diseases, metabolic diseases, autoimmune diseases and/or fibrotic diseases, is provided to thereby regulate the intracellular concentration of ATF3, and can thus be used for the treatment of inflammatory diseases, metabolic diseases, autoimmune diseases and/or fibrotic diseases. Moreover, the disease treatment effect can be enhanced by further fusing a peptide having intracellular permeability and an inflammation inhibitory function to the peptide.

    NOVEL USE OF PEPTIDE FOR INHIBITING FUNCTIONS AND EXPRESSIONS OF MULTIPLE DISEASE BIOMARKERS
    10.
    发明申请
    NOVEL USE OF PEPTIDE FOR INHIBITING FUNCTIONS AND EXPRESSIONS OF MULTIPLE DISEASE BIOMARKERS 有权

    公开(公告)号：US20210340182A1

    公开(公告)日：2021-11-04

    申请号：US17272010

    申请日：2019-08-29

    Applicant: NIBEC CO., LTD.

    Inventor： Yoon Jeong Park ,  Chong-Pyoung Chung ,  Jue-Yeon Lee

    IPC: C07K7/08 ,  A61K45/06

    Abstract: The present invention relates to a novel use of a peptide for inhibiting the functions and expressions of multiple disease biomarkers, and more specifically, to a pharmaceutical composition for treating or preventing inflammation, metabolic diseases or fibrotic diseases, the composition comprising, as an active ingredient, any one or more peptide among peptides which are represented by the amino acid sequences of SEQ ID NOs: 1 to 8, and which, for histone deacetylase 5 (HDAC5), GDF15 and ATF3 which are biomarkers associated with inflammation, metabolic diseases or fibrotic diseases, have the functions of inhibiting HDAC5 phosphorylation, inhibiting the expression of the GDF15 protein and inhibiting the expression of the ATF3 protein. The peptide, according to the present invention, enables the triple-blocking of the biomarkers associated with inflammation, metabolic diseases or fibrotic diseases by inhibiting HDAC phosphorylation, inhibiting the expression of the GDF15 protein and inhibiting the expression of the ATF3 protein, and thus the production of inflammatory cytokine may be reduced, and thus the peptide is effective in preventing and treating inflammatory, metabolic or fibrotic diseases.

Patent Agency Ranking